Limited Clinical Relevance of Mitochondrial DNA Mutation and Gene Expression Analyses in Ovarian Cancer
Author Information
Author(s): Piotr Bragoszewski, Jolanta Kupryjanczyk, Ewa Bartnik, Andrzej Rachinger, Jerzy Ostrowski
Primary Institution: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Hypothesis
Do mutations in the mitochondrial D-loop region and/or the level of mitochondrial gene expression influence the clinical course of human ovarian carcinomas?
Conclusion
The study indicates limited clinical relevance of mitochondrial molecular analyses in ovarian carcinomas.
Supporting Evidence
- 57% of ovarian cancer samples had somatic mutations in the D-loop sequence.
- No significant association was found between mitochondrial DNA mutation status or gene expression and clinicopathologic parameters.
- The expression of the mitochondrial gene RNR1 may predict tumor sensitivity to chemotherapy.
Takeaway
This study looked at changes in mitochondrial DNA in ovarian cancer and found that they don't really help doctors understand or treat the disease better.
Methodology
The study sequenced a 1320-base-pair DNA fragment of the mitochondrial genome in 54 cancer samples and quantified six mitochondrial gene transcripts in 62 cancer tissues using real-time RT-PCR.
Limitations
The study suggests that the clinical utility of mitochondrial molecular tests in ovarian cancer is questionable and requires further validation.
Participant Demographics
The study included 62 ovarian cancer samples from patients with FIGO IIC-IV disease, with a majority being serous carcinomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website